TABLE 2 Effect of recombinant human erythropoietin on hemoglobin response and transfusion rates: FDA license indication studies.
From the following article:
Cancer-related anemia and recombinant human erythropoietin—an updated overview
Julia Bohlius, Olaf Weingart, Sven Trelle and Andreas Engert
BACK TO ARTICLE| Reference | Patients randomized | Patients evaluated | Cancer and anticancer treatment | Hemoglobin eligibility criteria (g/dl) | Treatment with study drug | Target hematocrit | Proportion of patients with Hb response,a EPO vs control | Proportion of patients transfused, EPO vs control |
|---|---|---|---|---|---|---|---|---|
aIn all studies hemoglobin response is defined as hematocrit increase of 6% from baseline, independent of transfusion. | ||||||||
EPO, erythropoietin; Hb, hemoglobin; s.c., subcutaneous; t.i.w., three times a week. | ||||||||
| Abels (1993)87 | 124 | 118 | Solid and hematologic cancers without chemotherapy |  10.5 | Epoetin alfa 100 IU/kg t.i.w. s.c. for 8 weeks | Not reported | 32% vs 11% | 33% vs 38% |
| Case et al. (1993)88 | 157 | 153 | Solid and hematologic cancers nonplatinum-based chemotherapy | 10.5 | Epoetin alfa 150 IU/kg t.i.w. s.c. for 12 weeks | 38–40% | 58% vs 14% | 41% vs 49% |
| Henry et al. (1995)89 | 132 | 125 | Solid and hematologic cancers platinum-based chemotherapy | 10.5 | Epoetin alfa 150 IU/kg t.i.w. s.c. for 12 weeks | 38–40% | 48% vs 7% | 53% vs 67% |